PET Scan Can Help Identify Treatment Options for Men With Prostate Cancer and Rising PSA

CancerConnect News: For prostate cancer patients who have rising levels of prostate specific-antigen PSA which is monitored for cancer recurrence following radical prostatectomy, early treatment makes a difference. A recent study suggests that PET scans can identify which prostate cancer patients would benefit from additional radiation treatment.

Many individuals treated for prostate cancer eventually develop a recurrence, which are often detected when their PSA levels start rising on routine blood tests. Unfortunately, standard imaging tests aren’t good at determining where cancer cells are located.  68Ga-PSMA PET/CT imaging, or PSMA-PET imaging for short, represents a major advance in detecting prostate cancer.

The PSMA-PET imaging test works by marking an antigen receptor that sits on the surface of every prostate cancer cell, called PSMA, with a radioactive peptide, Gallium-68. This process allows the cancer cells to be detected wherever they are located throughout the body and better detects prostate cancer recurrences.

In the current study patients underwent imaging with a PSMA PET scan and had treatment based on the results of the scan findings.

Among patients of aged care melbourne with a negative PSMA, 44% were treated with subsequent radiation therapy and 56% were not. The negative PSMA group that received radiation had an 85% treatment response suggesting that additional radiation therapy was helpful in controlling the cancer. The study suggests that PSMA PET can help predict which individuals with a rising PSA may have more localized disease that can be treated with radiation. Men with negative or fossa-confined PSMA had the highest treatment response.  Men with cancerous nodes or distant disease have a poor response and should consider more systemic treatment.

The study authors suggest tht the results of the study show that PSMA PET may be more predictive of a treatment response than PSA level, surgical margins or seminal vesical involvement.



Copyright © 2018 CancerConnect. All Rights Reserved.